Phase 1 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with certain B-cell blood cancers (a type of cancer affecting white blood cells), confirmed by standard diagnostic criteria. For the first part of the trial (dose escalation), eligible cancer types include mantle cell lymphoma, marginal zone lymphoma, Waldenström macroglobulinemia, diffuse large B-cell lymphoma (DLBCL, including several subtypes), and follicular lymphoma grades 1 to 3B. For the second part (dose expansion), eligible types are DLBCL, follicular lymphoma grades 1 to 3B, or mantle cell lymphoma, depending on the specific group within that part.
• People whose cancer has come back, stopped responding to treatment, or who could not tolerate at least 2 or more previous treatments that were expected to help, and for whom no other suitable standard treatment is currently available locally.
• People with a type of slower-growing lymphoma (called indolent non-Hodgkin's lymphoma) must also meet specific guidelines that indicate their disease currently needs treatment.
• People who have previously had an allogeneic stem cell transplant (a transplant using donor cells) must have been stable and off anti-rejection medicines for at least 3 months.
• People enrolled in certain parts of the trial may need to provide a fresh tumour biopsy sample taken during treatment, from the same area as the baseline sample (this requirement may be waived by the trial medical monitor if a biopsy would be risky or difficult based on tumour location).
• People who have previously been treated with a therapy targeting a protein called CD79b must have had a tumour biopsy taken after that most recent CD79b-targeting treatment (this requirement may also be waived by the trial medical monitor under certain circumstances).
• People who are in good general health, rated 0 or 1 on a standard activity scale, meaning they are either fully active or have minor limitations in physically strenuous activity but can carry out light work.
• People whose blood test results meet specific levels set out in the trial guidelines, tested during the screening period before the first dose.
• People who can provide a tumour tissue sample — either a recently archived sample or a new biopsy taken during screening — suitable for laboratory testing (this may be waived by the trial medical monitor if a biopsy would be risky or difficult).

Who may not be able to join:

• People who have a history of a lung condition called interstitial lung disease or pneumonitis that needed treatment with steroid medicines, or who currently show signs of either condition.
• People who have received any anti-cancer treatment — including chemotherapy, radiation, small molecule drugs, experimental therapies, or biological medicines — within 14 days (or within 5 half-lives of that medicine, whichever is shorter) before the first dose of the study treatment.
• People who have received a treatment specifically targeting the CD79b protein within 4 weeks (or within 5 half-lives of that medicine, whichever is shorter) before the first dose of the study treatment.
• People who have previously been treated with a type of medicine called an antibody-drug conjugate that contains a topoisomerase I inhibitor (a specific kind of cancer-fighting agent attached to an antibody).

Important: Always verify eligibility with the trial site directly before applying.